08:29 uur 05-10-2020

VALBIOTIS integreert de EnterNext© PEA-PME 150 Index van Euronext Parijs

LA ROCHELLE, Frankrijk– (BUSINESS WIRE) – Regelgevend nieuws:

VALBIOTIS (Parijs: ALVAL) (Euronext: ALVAL), een onderzoeks- en ontwikkelingsbedrijf dat zich inzet voor wetenschappelijke innovatie voor het voorkomen en bestrijden van stofwisselingsziekten, kondigt aan dat het is toegetreden tot de EnterNext© PEA-PME 150-index vanaf de handelssessie van 1 oktober 2020 .

De EnterNext© PEA-PME 150 is een beursindex die representatief is voor Franse aandelen die in aanmerking komen voor PEA-PME. EnterNext© PEA-PME 150 is groter dan de CAC PME en bestaat uit 150 kleine en middelgrote aandelen die tot de meest liquide behoren.

VALBIOTIS Integrates The EnterNext© PEA-PME 150 Index From Euronext Paris

LA ROCHELLE, France–(BUSINESS WIRE)– Regulatory News:

VALBIOTIS (Paris:ALVAL) (Euronext: ALVAL), a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, announces that it has joined the EnterNext© PEA-PME 150 index as of the October 1st, 2020 trading session.

The EnterNext© PEA-PME 150 is a stock market index representative of French equities eligible for PEA-PME. Larger than the CAC PME, EnterNext© PEA-PME 150 is made up of 150 small and medium-sized stocks that are among the most liquid.

Jocelyn PINEAU, Chief Finance Officer, member of the management Board of VALBIOTIS stated: “We are proud to be part of the EnterNext© index PEA-PME 150 which values the most liquid French midcap stocks. This achievement thus rewards the growing interest of investors in our value, whether professional or private. Less than four years after our IPO, this is a real satisfaction and an encouragement to continue our constant efforts to communicate to the market on the progress of our business plan and the execution of our strategy.


VALBIOTIS is a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases in response to unmet medical needs.

VALBIOTIS has adopted an innovative approach, aiming to revolutionize healthcare by developing a new class of nutritional health solutions designed to reduce the risk of major metabolic diseases, based on a multi-target approach and made possible by the use of plant-based ingredients.

Its products are intended to be licensed to players in the health world.

VALBIOTIS was founded in La Rochelle in early 2014 and has formed numerous partnerships with top academic centers. The Company has established three sites in France – Périgny, La Rochelle (17) and Riom (63).

VALBIOTIS is a member of the “BPI Excellence” network and received “Innovative Company“ status awarded by BPI France. Valbiotis has also been awarded “Young Innovative Company” status and has received major financial support from the European Union for its research programs via the European Regional Development Fund (ERDF). VALBIOTIS is a PEA-SME eligible company.

Find out more about VALBIOTIS: www.valbiotis.com


ISIN code: FR0013254851

Mnemonic code: ALVAL

EnterNext © PEA-PME 150


This press release contains forward-looking statements about VALBIOTIS’ objectives, based on rational hypotheses and the information available to the company at the present time. However, in no way does this constitute a guarantee of future performance, and these projections may be affected by changes in economic conditions and financial markets, as well as a certain number of risks and uncertainties, including those described in the VALBIOTIS registration document, filed with the French Financial Markets Regulator (AMF) on 31 July 2020 (application number R 120–018). This document is available on the Company’s website (www.valbiotis.com).

This press release, as well as the information contained herein, does not constitute an offer to sell or subscribe to, or a solicitation to purchase or subscribe to, VALBIOTIS’ shares or securities in any country.




+33 5 46 28 62 58



Stéphane RUIZ

+33 1 56 88 11 14


Check out our twitter: @NewsNovumpr